# ZBTB4

## Overview
ZBTB4 is a gene that encodes the zinc finger and BTB domain-containing protein 4, a transcriptional repressor involved in regulating gene expression and maintaining genomic stability. The protein is characterized by C2H2 zinc finger domains, which facilitate DNA binding, and a BTB/POZ domain, which is crucial for protein-protein interactions and recruitment of chromatin remodeling corepressors (Xiang2020&lt; p&gt; Expression; RousselGervais2017Loss). ZBTB4 plays a significant role in repressing the p21 gene, influencing cell cycle arrest and apoptosis in response to p53 activation (Weber2008Zbtb4). It is also involved in maintaining genome stability, with its depletion leading to increased aneuploidy and genomic abnormalities (RousselGervais2017Loss). The protein's interactions with other proteins, such as HIPK2, which phosphorylates and downregulates ZBTB4, highlight its role in cellular stress responses (Yamada2009The). Alterations in ZBTB4 expression have been linked to various cancers, underscoring its potential as a prognostic marker and therapeutic target (Dong2021Glioma; Yang2023Identification).

## Structure
ZBTB4 is a protein characterized by the presence of C2H2 zinc finger domains and a BTB/POZ domain, which are crucial for its function as a transcriptional repressor. The zinc finger domains facilitate DNA binding, particularly to methylated CpG sites, while the BTB domain is involved in protein-protein interactions and recruitment of chromatin remodeling corepressors (Xiang2020&lt; p&gt; Expression; RousselGervais2017Loss). 

The protein also contains a proline-rich domain and an acidic domain, which may contribute to its structural stability and interaction with other proteins (Yamada2009The). ZBTB4 is subject to post-translational modifications, such as phosphorylation by the protein kinase HIPK2, which can lead to its degradation (Yamada2009The). 

Alternative splicing of the ZBTB4 gene can result in different isoforms, although specific details on these isoforms are not provided in the context. The protein's localization to chromocenters, which are regions of highly methylated DNA, is lost in cells lacking DNA methylation, indicating the importance of its DNA-binding domains for proper cellular localization (RousselGervais2017Loss).

## Function
The ZBTB4 gene encodes a transcriptional repressor protein that plays a significant role in regulating gene expression in healthy human cells. ZBTB4 is involved in the repression of the p21 gene, which is crucial for cell cycle arrest and the DNA damage response. It binds to methylated DNA and forms a complex with the Sin3/histone deacetylase co-repressor and Miz1 to repress p21 expression, thereby influencing the balance between cell cycle arrest and apoptosis in response to p53 activation (Weber2008Zbtb4). 

ZBTB4 is also essential for maintaining genome stability and proper mitotic checkpoint function. Its depletion leads to increased aneuploidy and genomic abnormalities, such as micronuclei and binucleated cells, indicating issues with chromosome segregation during mitosis (RousselGervais2017Loss). The protein is active in the nucleus, where it affects chromatin remodeling and influences cellular proliferation and differentiation (Filion2006A). 

ZBTB4's interaction with the protein kinase HIPK2, which phosphorylates and downregulates ZBTB4, highlights its role in cellular responses to stress and its potential impact on cell survival and proliferation (Yamada2009The). Overall, ZBTB4 is crucial for maintaining genomic integrity and regulating the cell cycle in healthy cells.

## Clinical Significance
Alterations in the expression of the ZBTB4 gene have been implicated in various cancers. In glioma, ZBTB4 expression is downregulated, with the degree of downregulation correlating with the pathological grade of the tumor. This downregulation is associated with enhanced glycolipid metabolism and cell proliferation, suggesting a tumor-suppressive role for ZBTB4 in glioma (Dong2021Glioma). In colorectal cancer (CRC), ZBTB4 is significantly downregulated, and its low expression is linked to metastasis and poor prognosis, indicating its potential as a prognostic marker (Xiang2020&lt; p&gt; Expression).

In pancreatic cancer, ZBTB4 is identified as an immunological biomarker that inhibits cancer cell proliferation and invasion. Reduced expression of ZBTB4 in pancreatic cancer tissues is associated with poor prognosis and immune infiltration, highlighting its clinical significance (Yang2023Identification). In Ewing sarcoma, low ZBTB4 expression correlates with poorer overall survival, and its overexpression inhibits cell proliferation and induces apoptosis, suggesting a tumor-suppressive function (Yu2018Tumor).

The loss of ZBTB4 is also linked to increased genomic instability and aneuploidy, contributing to tumorigenesis in various cancers, including breast and prostate cancer (RousselGervais2017Loss). These findings underscore the importance of ZBTB4 in cancer progression and its potential as a therapeutic target.

## Interactions
ZBTB4 is a transcriptional repressor that interacts with several proteins and nucleic acids, playing a significant role in gene regulation. It forms a DNA-binding complex with Miz1 on the P21CIP1 promoter, where it enhances Miz1's DNA binding and represses transcription. This interaction is independent of DNA binding and has been confirmed in various cell types, including HEK293 and colon carcinoma cells (Weber2008Zbtb4). ZBTB4 also interacts with the Sin3a and Sin3b proteins, which are part of the Sin3 complex known to recruit histone deacetylases (HDACs). This interaction facilitates the recruitment of HDAC activity to the P21CIP1 promoter, contributing to transcriptional repression (Weber2008Zbtb4).

ZBTB4 is phosphorylated by the protein kinase HIPK2, leading to its degradation. This interaction occurs both in vitro and in vivo, with HIPK2 phosphorylating several conserved residues of ZBTB4. The phosphorylation marks ZBTB4 for ubiquitination and proteasomal degradation, particularly in response to DNA damage (Yamada2009The). ZBTB4 also competes with Sp1 for binding to GC-rich sites in the promoters of pro-tumoral genes, such as VEGF and VEGFR, thereby repressing their transcription (RousselGervais2017Loss). These interactions highlight ZBTB4's role in regulating gene expression and maintaining genomic stability.


## References


[1. (Dong2021Glioma) Weiwei Dong, Xiaobai Liu, Chunqing Yang, Di Wang, Yixue Xue, Xuelei Ruan, Mengyang Zhang, Jian Song, Heng Cai, Jian Zheng, and Yunhui Liu. Glioma glycolipid metabolism: msi2–snord12b–fip1l1–zbtb4 feedback loop as a potential treatment target. Clinical and Translational Medicine, May 2021. URL: http://dx.doi.org/10.1002/ctm2.411, doi:10.1002/ctm2.411. This article has 25 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/ctm2.411)

[2. (Yamada2009The) D Yamada, R Pérez-Torrado, G Filion, M Caly, B Jammart, V Devignot, N Sasai, P Ravassard, J Mallet, X Sastre-Garau, M L Schmitz, and P -A Defossez. The human protein kinase hipk2 phosphorylates and downregulates the methyl-binding transcription factor zbtb4. Oncogene, 28(27):2535–2544, May 2009. URL: http://dx.doi.org/10.1038/onc.2009.109, doi:10.1038/onc.2009.109. This article has 33 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/onc.2009.109)

[3. (Weber2008Zbtb4) Axel Weber, Judith Marquardt, David Elzi, Nicole Forster, Sven Starke, Andre Glaum, Daisuke Yamada, Pierre-Antoine Defossez, Jeffrey Delrow, Robert N Eisenman, Holger Christiansen, and Martin Eilers. Zbtb4 represses transcription of p21cip1 and controls the cellular response to p53 activation. The EMBO Journal, 27(11):1563–1574, May 2008. URL: http://dx.doi.org/10.1038/emboj.2008.85, doi:10.1038/emboj.2008.85. This article has 82 citations.](https://doi.org/10.1038/emboj.2008.85)

[4. (Filion2006A) Guillaume J. P. Filion, Svetlana Zhenilo, Sergey Salozhin, Daisuke Yamada, Egor Prokhortchouk, and Pierre-Antoine Defossez. A family of human zinc finger proteins that bind methylated dna and repress transcription. Molecular and Cellular Biology, 26(1):169–181, January 2006. URL: http://dx.doi.org/10.1128/mcb.26.1.169-181.2006, doi:10.1128/mcb.26.1.169-181.2006. This article has 261 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.26.1.169-181.2006)

[5. (Yang2023Identification) Zhe Yang, Feiran Chen, Feng Wang, Xiubing Chen, Biaolin Zheng, Xiaomin Liao, Zhejun Deng, Xianxian Ruan, Jing Ning, Qing Li, Haixing Jiang, and Shanyu Qin. Identification of zbtb4 as an immunological biomarker that can inhibit the proliferation and invasion of pancreatic cancer. BMC Cancer, March 2023. URL: http://dx.doi.org/10.1186/s12885-023-10749-x, doi:10.1186/s12885-023-10749-x. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12885-023-10749-x)

[6. (Yu2018Tumor) Yongxin Yu, Ruguo Shang, Yunzhou Chen, Jiehua Li, Zhichao Liang, Jianwei Hu, Kai Liu, and Chao Chen. Tumor suppressive zbtb4 inhibits cell growth by regulating cell cycle progression and apoptosis in ewing sarcoma. Biomedicine &amp; Pharmacotherapy, 100:108–115, April 2018. URL: http://dx.doi.org/10.1016/j.biopha.2018.01.132, doi:10.1016/j.biopha.2018.01.132. This article has 25 citations.](https://doi.org/10.1016/j.biopha.2018.01.132)

[7. (RousselGervais2017Loss) Audrey Roussel-Gervais, Ikrame Naciri, Olivier Kirsh, Laetitia Kasprzyk, Guillaume Velasco, Giacomo Grillo, Pierre Dubus, and Pierre-Antoine Defossez. Loss of the methyl-cpg–binding protein zbtb4 alters mitotic checkpoint, increases aneuploidy, and promotes tumorigenesis. Cancer Research, 77(1):62–73, January 2017. URL: http://dx.doi.org/10.1158/0008-5472.CAN-16-1181, doi:10.1158/0008-5472.can-16-1181. This article has 47 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/0008-5472.CAN-16-1181)